Literature DB >> 18628757

Acid sphingomyelinase overexpression enhances the antineoplastic effects of irradiation in vitro and in vivo.

Eric L Smith1, Edward H Schuchman.   

Abstract

Exposure of cells or animals to stress frequently induces acid sphingomyelinase (ASM)-mediated ceramide production that leads to cell death. Consistent with this, overexpression of ASM in subcutaneous B16-F10 mouse melanomas, in combination with irradiation, resulted in tumors that were up to 12-fold smaller than irradiated control melanomas. Similarly, when irradiated melanomas were pretreated with a single, peritumoral injection of recombinant ASM (rhASM), the tumors were up to threefold smaller. The in vivo effect of ASM was likely due to enhanced cell death of the tumor cells themselves, as well as the surrounding microvascular endothelial cells. In vitro, rhASM had little or no effect on the growth of tumor cells, even in combination with irradiation. However, when the culture media was acidified to mimic the acidic microenvironment of solid tumors, rhASM-mediated cell death was markedly enhanced when combined with irradiation. Microscopic analysis suggested that this was associated with an increase in autophagy. rhASM has been produced for the treatment of the lysosomal storage disorder, type B Niemann-Pick disease, and is currently being evaluated in a phase-1 clinical trial. Based on the data presented in this article, we propose that further investigation of this protein and gene as antineoplastic agents also is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628757     DOI: 10.1038/mt.2008.145

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  20 in total

Review 1.  Ceramide-rich platforms in transmembrane signaling.

Authors:  Branka Stancevic; Richard Kolesnick
Journal:  FEBS Lett       Date:  2010-02-20       Impact factor: 4.124

Review 2.  Sphingolipids in the DNA damage response.

Authors:  Brittany Carroll; Jane Catalina Donaldson; Lina Obeid
Journal:  Adv Biol Regul       Date:  2014-11-18

Review 3.  Involvement of ceramide in cell death responses in the pulmonary circulation.

Authors:  Irina Petrache; Daniela N Petrusca; Russell P Bowler; Krzysztof Kamocki
Journal:  Proc Am Thorac Soc       Date:  2011-11

4.  Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis.

Authors:  Anna Moles; Núria Tarrats; Albert Morales; Marlene Domínguez; Ramón Bataller; Juan Caballería; Carmen García-Ruiz; José C Fernández-Checa; Montserrat Marí
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

Review 5.  Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.

Authors:  Suriyan Ponnusamy; Marisa Meyers-Needham; Can E Senkal; Sahar A Saddoughi; David Sentelle; Shanmugam Panneer Selvam; Arelis Salas; Besim Ogretmen
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

Review 6.  Lysosomal Biology in Cancer.

Authors:  Colin Fennelly; Ravi K Amaravadi
Journal:  Methods Mol Biol       Date:  2017

Review 7.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

Review 8.  Targeting the lysosome in cancer.

Authors:  Shengfu Piao; Ravi K Amaravadi
Journal:  Ann N Y Acad Sci       Date:  2015-11-24       Impact factor: 5.691

9.  A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.

Authors:  Razan Sheta; Christina M Woo; Florence Roux-Dalvai; Frédéric Fournier; Sylvie Bourassa; Arnaud Droit; Carolyn R Bertozzi; Dimcho Bachvarov
Journal:  J Proteomics       Date:  2016-04-17       Impact factor: 4.044

10.  Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.

Authors:  Radoslav Savić; Xingxuan He; Isabel Fiel; Edward H Schuchman
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.